Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Vizoovet
Zurich, Zurich, Switzerlandvizoovet.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Vizoovet is a Swiss veterinary biotechnology company specializing in advanced ophthalmic solutions for companion animals and horses. The company developed the first biomimetic tear film supplement designed specifically to match the unique physiological composition of animal tears, which differs significantly from human tears. Its flagship product, Vizoovet, is used to treat keratoconjunctivitis sicca (dry eye) and support the healing of corneal ulcers by restoring the natural protective layers of the ocular surface. By incorporating essential proteins and lipids, the company's technology aims to provide long-lasting lubrication and promote corneal health in veterinary patients.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small moleculeProteinLipid-based formulation
- Industry
- Veterinary
Beyond the preview
Go deeper on Vizoovet.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vizoovet.